Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of KN026 Combination Chemotherapy ± KN046 in HER2-Positive Advanced Colorectal Cancer and Biliary Tract Cancer as First-Line Treatment： a Phase Ⅱ Study

NCT05985707 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT05985707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05985707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of KN026 Combination Chemotherapy ± KN046 in HER2-Positive Advanced Colorectal Cancer and Biliary Tract Cancer as First-Line Treatment： a Phase Ⅱ Study
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 15, 2023
Completion date
December 31, 2026
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive biliary tract cancer, her2-positive colorectal cancer